Business Wire

Seoul Viosys to Develop a Cancer Diagnosis Technology for Companion Animals with Violeds Technology

Share

Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that it has developed an advanced concept technology for early diagnosis of cancer in companion animals with its ultraviolet LED Violeds technology through clinical testing conducted by scientists at the University of Ulsan, based in South Korea.

According to Seoul Viosys’ research team, companion animals have a high incidence of cancer as humans, but it has difficulty in early diagnosis of cancer. So Seoul Viosys is in the process of developing a technology that can be applied not only in animals but also in human cancer diagnosis. The early cancer diagnosis method using Violeds light provides a profound study results to show significantly higher sensitivity in detecting cancer than the conventional diagnosis methods and enable to detect all incident cancers.

Seoul Viosys conducted comparative experiments with blood from healthy dogs and from cancer diseased dogs using a biomarker that can be easily collected in this clinical test. As a result, it’s confirmed that cancer diagnosis is possible by only one drop of blood. Seoul Viosys already applied for number of related patents.

Reactive Oxygen Species, ROS caused by various exogenous and endogenous factors damaged to DNA in cells and it can be pathological basis for cancer when this DNA is not repaired in a timely manner. Even though level of DNA damage on cancer cells due to oxidative stress is higher than healthy cells, the difference between the two results is small and it’s difficult to distinguish perfectly. However, Violeds technology provides the advantage that can be able to detect this delicate difference.

“Through the results of the pre-clinical testing with comet assay, an uncomplicated and sensitive technique for the detection of DNA damage at the level of the individual mononuclear cell, by research group of Ulsan University, Seoul Viosys demonstrates that Violeds technology has the performance for significantly high level of 95% sensitivity in detecting cancer for companion animals, but improvement for specificity is needed,” said research team at Seoul Viosys.

“If we achieve the improved level of specificity in the future, we will be able to make a positive contribution to a quantum jump in medical technology by enabling early cancer diagnosis with about a tenth price compared to conventional test kits. Seoul Viosys also expects this technology to be used for human cancer diagnosis in the future and looks for relevant and suitable research partners to achieve significant specificity,” added the team.

*Light and Violeds

Circadian rhythms as an internal clock that governs the body’s hormone levels and other biological processes such as sleep, wake, and eliminating waste from the body are based on a 24-hour cycle. It is based on natural sunlight, under which all animals and plants on the earth have evolved over 3.9 billion years, being with the beginning of the Earth 4.6 billion years ago. Seoul Viosys has recently launched air purifiers with Violeds light technology proven to sterilize various harmful bacteria and variants of coronavirus. Tracking traces of light is difficult, but if you can bend the light around the Earth, it will orbit 7.5 times per second. Also, it takes 8 minutes for light to reach Earth from the Sun, and hundreds of millions of years from distant galaxies. It is unprecedented that this light may also be used in cancer diagnosis.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Seoul Semiconductor Co., Ltd.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

North America
Andrew Smith
Email: andrew.smith@seoulsemicon.com

Sales Contacts:
Americas
Mike Berens
mberens@s-et.com

Asia
Dong Ju Kim
djkim@seoulviosys.com

Europe
Marko Hofmann
marko.hofmann@seoulviosys.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 18:30:00 EET | Press release

Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer

Andersen Consulting Bolsters Capabilities with BMA25.11.2025 16:30:00 EET | Press release

Andersen Consulting broadens its sustainability and business transformation capabilities through a Collaboration Agreement with BMA, a South Africa-based firm advancing manufacturing competitiveness and inclusive industrial growth. Established over two decades ago, BMA works across manufacturing value chains—from producers to their clients—alongside government and development agencies to drive sustainable industrial competitiveness. Through its sector-focused industrial clusters, the firm delivers integrated services spanning industrial policy and strategy development, value chain strategy, manufacturing competitiveness and lean consulting, decarbonization and SME development—aligning stakeholders around shared priorities and scalable, long-term solutions. “Sustainable manufacturing goes beyond efficiency. It’s about creating ecosystems that are regenerative, resilient, and strategically aligned with long-term growth,” said Rob Stewart, CEO of BMA. “Many of the organizations we work wi

Pure Lithium Receives Saudi Patent for Vertically Integrated Lithium Metal Battery Technology25.11.2025 15:20:00 EET | Press release

Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the Kingdom of Saudi Arabia has granted the company a foundational patent titled “Vertically Integrated Pure Lithium Metal Production and Lithium Battery Production.” This broad patent covers technology that combines lithium extraction, anode production and battery manufacturing. Pure Lithium’s Brine to Battery™ is a registered trademark in the Kingdom of Saudi Arabia, planting a strong base of intellectual property in the region. “The technology is particularly relevant to Saudi Arabia because it is one of the places in the world with lithium-containing brines, and even has an abundance of vanadium, which is used in our second-generation battery,” said Founder, Chairman and CEO Emilie Bodoin. “In order to displace today’s lithium-ion battery, our vision is to create global battery hubs with closed loop supply chains, not just in the U.S., but in the many places in the world whe

‘BLUE LOCK - TOKYO EGOIST -’ kicks off on Saturday, November 2225.11.2025 15:07:00 EET | Press release

In its efforts to promote nighttime tourism, the Tokyo Metropolitan Government is developing new attractions that illuminate the capital after dark. As part of this initiative, projection mapping is being presented year-round on the iconic Tokyo Metropolitan Government Building No. 1, transforming its façade into a canvas of light and sound. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251121922505/en/ ©Muneyuki Kaneshiro, Yusuke Nomura, KODANSHA/BLUE LOCK Production Committee. A brand-new production inspired by the internationally popular soccer anime“BLUE LOCK”, titled BLUE LOCK – TOKYO EGOIST –, began screening on Saturday, November 22. On the first day of the screening, a mini-event was held at the Tokyo Metropolitan Government Plaza, where voice actors Kazuki Ura (voice of Yoichi Isagi) and Hiroshi Kamiya (voice of Jinpachi Ego) joined fans in celebrating the premiere. Scenes from the Opening Day of the New Production

Henderson Municipal Power & Light builds multigigabit FTTH network with Adtran fiber access technology25.11.2025 15:00:00 EET | Press release

Adtran today announced that Henderson Municipal Power & Light (HMP&L) is expanding broadband services across Henderson, Kentucky, using its open, intelligent fiber access platform. The highly scalable network leverages Adtran’s AI-powered insights to boost performance and reliability, enabling HMP&L to deliver fast, dependable multigigabit fiber-to-the-home (FTTH) services to residents and businesses. Fully integrated with Mosaic One and GLDS BroadHub® platforms, the solution simplifies network management and elevates the customer experience. The strong partnership between Adtran and HMP&L is enhancing access to digital resources, providing support to local businesses and driving regional economic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125416908/en/ Adtran’s fiber access technology is helping HMP&L drive multigigabit connectivity to homes and businesses throughout Henderson. “We’re committed to providing t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye